STOCK TITAN

Mineralys Therapeutics, Inc. - $MLYS STOCK NEWS

Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: $MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mineralys Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mineralys Therapeutics's position in the market.

Rhea-AI Summary
Mineralys Therapeutics to participate in fireside chat at Wells Fargo Securities Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will report its financial results for the second quarter ended June 30, 2023, on August 7, 2023, after the financial markets close. The conference call will take place on the same day at 4:30 p.m. ET. The company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. will be giving a presentation at the Jefferies Healthcare Conference on June 9, 2023. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
-
Rhea-AI Summary
Mineralys Therapeutics has announced the initiation of patient dosing in its lorundrostat pivotal clinical program for the treatment of uncontrolled or resistant hypertension. The company also plans to initiate a second pivotal trial and a Phase 2 trial to evaluate the safety and efficacy of lorundrostat. The topline data from the Advance-HTN trial is expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will report its Q1 2023 financial results on May 15, 2023, after the market close. The management team will host a conference call at 4:30 p.m. ET on the same day. A live webcast will be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
Mineralys Therapeutics, Inc.

Nasdaq:MLYS

MLYS Rankings

MLYS Stock Data

645.43M
23.00M
2.93%
92.49%
1.71%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
RADNOR

About MLYS

at mineralys therapeutics we aim to redefine hypertension diagnosis, management and treatment. we are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.